Synergistic anti-tumor effects of oncolytic virus therapy combined with sorafenib on human hepatocellular carcinoma
LI Yajiao1， LEI Wen2， QIN Yun1， YING Chang1， ZHOU Xiumei1
1.Xinyuan Institute of Medicine and Biotechnology， College of Life Sciences， Zhejiang Sci-Tech University， Hangzhou 310018；2.Department of Hematology， the First Affiliated Hospital， College of Medicine， Zhejiang University， Hangzhou 310003
Abstract：Human hepatocellular carcinoma is one of the most common and high fatal cancer in the world. In China， the liver cancer rates is the highest in the world. Many researchers put into the research of liver cancer and tried many ways and methods， but still couldn't find effective ways to cure hepatocellular carcinoma. In the recent years， oncolytic vaccinia virus become a promising novel way in cancer treatment because of its efficient anti-tumor effect， low side effects and good safety， and has been widely used in the treatment of cancer. Sorafenib， a new tumor-targeting kinase inhibitor， has shown its effective and safe chemotherapy drugs in treatment of HCC， and has already used in clinical trials. In the present study， we combined sorafenib with VV to explore its anti-tumor effects. Through in vitro experiments like MTT， Hoechst， Flow cytometry， Western blot and in vivo transplantation of tumor model and immunohistochemical analysis， it’s demonstrated that combination of sorafenib and vaccinia virus significantly inhibited the growth of tumor cells and promoted apoptosis of tumor cells. According to the result of mice transplanted tumor model， the date showed that with the extension of time， the combined group tumor size has a tendency to decline. Thus， the combination use of sorafenib and vaccinia virus might be a novel approach for liver cancer therapy.
2017, Vol. 51 
